Our research using an MC38 mouse subcutaneous tumor model indicated that the synergistic use of TF and anti‐CTLA‐4 led to a pronounced increase in CD8+ T‐cell infiltration and a suppression of tumor growth compared with the effects of TF, anti‐PD‐1, or anti‐CTLA‐4 alone. The gene discussed is CD8A; the disease is neoplasm.